Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 77Multiple Myeloma 40Lymphoma, Large B-Cell, Diffuse 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 37Lymphoma 37Lymphoma, Non-Hodgkin 27Leukemia 26Leukemia, Lymphocytic, Chronic, B-Cell 18Burkitt Lymphoma 18Recurrence 17Lymphoma, Mantle-Cell 17Lymphoma, Follicular 17Neoplasms, Plasma Cell 16Lymphoma, B-Cell 16Leukemia, Myeloid, Acute 16Neuroblastoma 12Hodgkin Disease 12Lymphoma, Large-Cell, Immunoblastic 11Myelodysplastic Syndromes 9Lymphoma, T-Cell, Peripheral 9Lymphoma, B-Cell, Marginal Zone 9Inflammatory Breast Neoplasms 9Triple Negative Breast Neoplasms 8Sarcoma 8Ovarian Neoplasms 8Immunoblastic Lymphadenopathy 7Neoplasm Metastasis 6Melanoma 6Leukemia, Myeloid, Chronic-Phase 6Hematologic Neoplasms 6

Interventions

Decitabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Hematopoietic System--Cancer × Cyclophosphamide × Clear all
NCT03654703 2018-08-31

Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AML

Capital Research Institute of Pediatrics

Phase 2 Unknown
100 enrolled

Hematopoietic System--Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡